Low-density lipoprotein cholesterol lowering and out-of-pocket cost of inclisiran therapy in the United States
These real-world data demonstrate significant LDL-C reductions within 1 year in patients who initiated inclisiran. Nearly all patients with Medicare had no OOP costs.
Authors
- Nihar R. Desai (ORCID: https://orcid.org/0000-0003-2384-2545)
- Nicholas W. Van Hise
- Xiaoli Niu
- Alan S. Brown
Institutions
- Novartis (Switzerland) (CH)
- Advocate Lutheran General Hospital (US)
- Yale University (US)
- Chicago Metro History Education Center (US)
Publication Details
- Journal
- Journal of clinical lipidology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.jacl.2026.02.010
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novartis Pharmaceuticals Corporation